JP2005534326A - アビポックスウイルスの力価を増加させるためのワクシニアウイルス宿主域遺伝子 - Google Patents
アビポックスウイルスの力価を増加させるためのワクシニアウイルス宿主域遺伝子 Download PDFInfo
- Publication number
- JP2005534326A JP2005534326A JP2004526814A JP2004526814A JP2005534326A JP 2005534326 A JP2005534326 A JP 2005534326A JP 2004526814 A JP2004526814 A JP 2004526814A JP 2004526814 A JP2004526814 A JP 2004526814A JP 2005534326 A JP2005534326 A JP 2005534326A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- host range
- cell
- gene
- range gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 200
- 241000700663 Avipoxvirus Species 0.000 title claims abstract description 156
- 241000700618 Vaccinia virus Species 0.000 title claims abstract description 109
- 230000003612 virological effect Effects 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 34
- 241000271566 Aves Species 0.000 claims abstract description 24
- 208000015181 infectious disease Diseases 0.000 claims abstract description 19
- 230000001965 increasing effect Effects 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 221
- 241000700605 Viruses Species 0.000 claims description 105
- 241000178270 Canarypox virus Species 0.000 claims description 60
- 108020004414 DNA Proteins 0.000 claims description 35
- 150000007523 nucleic acids Chemical group 0.000 claims description 32
- 229960005486 vaccine Drugs 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 230000010076 replication Effects 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 210000005260 human cell Anatomy 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 101150091263 E3L gene Proteins 0.000 claims description 11
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 208000007089 vaccinia Diseases 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 9
- 241000700662 Fowlpox virus Species 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 241000282412 Homo Species 0.000 claims description 6
- 101100332586 Vaccinia virus (strain Western Reserve) VACWR059 gene Proteins 0.000 claims description 6
- 108700024019 Vaccinia virus pK3 Proteins 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 230000006798 recombination Effects 0.000 claims description 5
- 238000005215 recombination Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 206010061598 Immunodeficiency Diseases 0.000 claims description 3
- 241000282520 Papio Species 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 108700010758 gag-pro Proteins 0.000 claims description 3
- 101150081889 gag-pro gene Proteins 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003362 replicative effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 101100234922 Swinepox virus (strain Kasza) LAP gene Proteins 0.000 description 26
- 101100382200 Vaccinia virus (strain Ankara) MVA018L gene Proteins 0.000 description 26
- 101100382201 Vaccinia virus (strain Copenhagen) C7L gene Proteins 0.000 description 26
- 101100382202 Vaccinia virus (strain Western Reserve) VACWR021 gene Proteins 0.000 description 26
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 22
- 239000003550 marker Substances 0.000 description 19
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 13
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 13
- 230000002238 attenuated effect Effects 0.000 description 13
- 239000005090 green fluorescent protein Substances 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000011575 calcium Substances 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 101150044735 C7L gene Proteins 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 108091029795 Intergenic region Proteins 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 230000029812 viral genome replication Effects 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 6
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 6
- 108020004440 Thymidine kinase Proteins 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 101100287463 Vaccinia virus (strain Copenhagen) HR gene Proteins 0.000 description 5
- 101100287464 Vaccinia virus (strain Western Reserve) VACWR032 gene Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229930193140 Neomycin Natural products 0.000 description 4
- 241000286209 Phasianidae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 101150003725 TK gene Proteins 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000239290 Araneae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700625 Poxviridae Species 0.000 description 2
- 208000005585 Poxviridae Infections Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 101900323187 Vaccinia virus Interferon antagonist C7 Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 101150003160 X gene Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 229940024231 poxvirus vaccine Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101150020569 B3R gene Proteins 0.000 description 1
- 101150081941 B4R gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 101150051883 C17L gene Proteins 0.000 description 1
- 101150020334 C18L gene Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108700005088 Fungal Genes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000651211 Homo sapiens Transcription factor PU.1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 101000836070 Rattus norvegicus Serine protease inhibitor A3L Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102100027654 Transcription factor PU.1 Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 101100534077 Vaccinia virus (strain Western Reserve) SPI-1 gene Proteins 0.000 description 1
- 101100437248 Vaccinia virus (strain Western Reserve) VACWR186 gene Proteins 0.000 description 1
- 241000587120 Vaccinia virus Ankara Species 0.000 description 1
- 241000700622 Vaccinia virus Copenhagen Species 0.000 description 1
- 101900001372 Vaccinia virus RNA-binding protein E3 Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- -1 antibiotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000700570 unidentified entomopoxvirus Species 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201189 | 2002-08-07 | ||
| PCT/EP2003/008359 WO2004015118A1 (en) | 2002-08-07 | 2003-07-29 | Vaccinia virus host range genes to increase the titer of avipoxviruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005534326A true JP2005534326A (ja) | 2005-11-17 |
| JP2005534326A5 JP2005534326A5 (enExample) | 2006-09-07 |
Family
ID=31502636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004526814A Pending JP2005534326A (ja) | 2002-08-07 | 2003-07-29 | アビポックスウイルスの力価を増加させるためのワクシニアウイルス宿主域遺伝子 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7473536B2 (enExample) |
| EP (2) | EP1529113B1 (enExample) |
| JP (1) | JP2005534326A (enExample) |
| AT (1) | ATE504653T1 (enExample) |
| AU (1) | AU2003255315A1 (enExample) |
| CA (1) | CA2489301A1 (enExample) |
| DE (1) | DE60336653D1 (enExample) |
| WO (1) | WO2004015118A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023277069A1 (enExample) * | 2021-06-30 | 2023-01-05 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| DE60336653D1 (de) * | 2002-08-07 | 2011-05-19 | Bavarian Nordic As | Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| DK1536015T3 (da) * | 2003-11-24 | 2008-02-18 | Bavarian Nordic As | Promotorer til ekspression i modificeret vacciniavirus Ankara |
| ES2315096B1 (es) * | 2006-05-13 | 2009-12-30 | Consejo Superior De Investigaciones Cientificas | Vectores en los que se inserta el gen c7l y uso de los mismos en la fabricacion de vacunas y de composiciones para terapia genica. |
| EP2023954B1 (en) * | 2006-05-19 | 2013-07-17 | Sanofi Pasteur, Inc. | Immunological composition |
| EP2424999A1 (en) | 2009-04-30 | 2012-03-07 | Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) | Modified immunization vectors |
| EP2668201A2 (en) | 2011-01-28 | 2013-12-04 | Sanofi Pasteur SA | Immunological compositions comprising hiv gp41 polypeptide derivatives |
| WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
| PL3063278T3 (pl) * | 2013-11-01 | 2018-08-31 | Sementis Limited | Wytwarzanie wektora wirusowego |
| SG11202101291VA (en) * | 2018-08-08 | 2021-03-30 | Univ Arizona State | Method for improved poxvirus yields |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000003030A2 (en) * | 1998-07-10 | 2000-01-20 | Schering-Plough Ltd. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
| JP2001514518A (ja) * | 1997-03-12 | 2001-09-11 | ヴァイロジェネティクス コーポレイション | 発現の向上したベクター並びにその製造および使用方法 |
| JP2001514519A (ja) * | 1997-03-12 | 2001-09-11 | ヴァイロジェネティクス コーポレイション | 発現が増強されたベクターならびにそれらの作出方法および用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| AU570940B2 (en) | 1982-11-30 | 1988-03-31 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Process for producing poxvirus recombinants for expression offoreign genes |
| WO1992015672A1 (en) * | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| ID19548A (id) | 1996-09-24 | 1998-07-23 | Bavarian Nordic Res Inst As | Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin |
| FR2811766B1 (fr) | 2000-07-13 | 2002-09-27 | Tabacs & Allumettes Ind | Procede de caracterisation de la compacite d'objets tels que des cigarettes ou des filtres |
| AU2002246829A1 (en) * | 2000-12-22 | 2002-07-30 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health A | Methods to control the host range of retroviral vectors |
| DE60336653D1 (de) * | 2002-08-07 | 2011-05-19 | Bavarian Nordic As | Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren |
-
2003
- 2003-07-29 DE DE60336653T patent/DE60336653D1/de not_active Expired - Lifetime
- 2003-07-29 EP EP03784104A patent/EP1529113B1/en not_active Expired - Lifetime
- 2003-07-29 US US10/524,043 patent/US7473536B2/en not_active Expired - Fee Related
- 2003-07-29 EP EP10008652A patent/EP2264178A1/en not_active Withdrawn
- 2003-07-29 CA CA002489301A patent/CA2489301A1/en not_active Abandoned
- 2003-07-29 JP JP2004526814A patent/JP2005534326A/ja active Pending
- 2003-07-29 AU AU2003255315A patent/AU2003255315A1/en not_active Abandoned
- 2003-07-29 AT AT03784104T patent/ATE504653T1/de not_active IP Right Cessation
- 2003-07-29 WO PCT/EP2003/008359 patent/WO2004015118A1/en not_active Ceased
-
2008
- 2008-08-26 US US12/198,220 patent/US20090162935A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001514518A (ja) * | 1997-03-12 | 2001-09-11 | ヴァイロジェネティクス コーポレイション | 発現の向上したベクター並びにその製造および使用方法 |
| JP2001514519A (ja) * | 1997-03-12 | 2001-09-11 | ヴァイロジェネティクス コーポレイション | 発現が増強されたベクターならびにそれらの作出方法および用途 |
| WO2000003030A2 (en) * | 1998-07-10 | 2000-01-20 | Schering-Plough Ltd. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023277069A1 (enExample) * | 2021-06-30 | 2023-01-05 | ||
| WO2023277069A1 (ja) * | 2021-06-30 | 2023-01-05 | 株式会社レプリテック | マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター |
| WO2024004235A1 (ja) * | 2021-06-30 | 2024-01-04 | 株式会社レプリテック | マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター |
| JP7633725B2 (ja) | 2021-06-30 | 2025-02-20 | 株式会社レプリテック | マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2264178A1 (en) | 2010-12-22 |
| US20060039928A1 (en) | 2006-02-23 |
| ATE504653T1 (de) | 2011-04-15 |
| CA2489301A1 (en) | 2004-02-19 |
| DE60336653D1 (de) | 2011-05-19 |
| AU2003255315A1 (en) | 2004-02-25 |
| US20090162935A1 (en) | 2009-06-25 |
| WO2004015118A1 (en) | 2004-02-19 |
| US7473536B2 (en) | 2009-01-06 |
| EP1529113B1 (en) | 2011-04-06 |
| EP1529113A1 (en) | 2005-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101005630B1 (ko) | 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는재조합 수두 바이러스 | |
| US20090162935A1 (en) | Vaccinia virus host range genes to increase the titer of avipoxviruses | |
| JP2011067219A (ja) | 改変ワクシニアウイルスアンカラにおける発現用プロモーター | |
| ES2288634T3 (es) | Poxvirus recombinante que comprende al menos dos promotores ati de la viruela de las vacas. | |
| ES2256747T3 (es) | Expresion de genes en el virus de la vacuna modificado, usando el promotor ati de la viruela de la vaca. | |
| HK1170772A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1156979A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060721 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060721 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090915 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090916 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100527 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101019 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110114 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20110114 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110121 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110208 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110131 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111213 |